• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗PD-1治疗诱发并与不明原因神经系统疾病相关的大疱性类天疱疮的迟发性皮肤表现

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

作者信息

Wang Xiaoxiao, Suppa Mariano, Bruderer Pascal, Sirtaine Nicolas, Aspeslagh Sandrine, Kerger Joseph

机构信息

Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

出版信息

Case Rep Oncol. 2021 Jun 15;14(2):861-867. doi: 10.1159/000514806. eCollection 2021 May-Aug.

DOI:10.1159/000514806
PMID:34248552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8255709/
Abstract

Immunotherapy has become the standard of care for various cancer types. The widespread use of immune checkpoints inhibitors confronts us with a whole range of novel immune-related adverse events. Skin toxicity is one of the most frequent adverse events. In this article, we report a case of anti-PD-1 induced late bullous pemphigoid (BP) with mucosal erosions and associated with a troublesome neurological disorder of undetermined origin in a patient with metastatic melanoma. Skin biopsy was essential to make the diagnosis and rapid initiation of systemic prednisolone played a role in favorable clinical outcome of BP. We will discuss the difficulty of early diagnosis of BP, its unusual association with neurological disorders, and the specific management of this particular dermatological entity.

摘要

免疫疗法已成为多种癌症类型的标准治疗方法。免疫检查点抑制剂的广泛应用使我们面临一系列全新的免疫相关不良事件。皮肤毒性是最常见的不良事件之一。在本文中,我们报告了1例抗程序性死亡蛋白1(PD-1)诱导的迟发性大疱性类天疱疮(BP),伴有黏膜糜烂,并与1例转移性黑色素瘤患者不明原因的棘手神经系统疾病相关。皮肤活检对于确诊至关重要,迅速开始全身使用泼尼松龙对BP的良好临床结局起到了作用。我们将讨论BP早期诊断的困难、其与神经系统疾病的异常关联以及这一特殊皮肤病实体的具体管理。

相似文献

1
A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.抗PD-1治疗诱发并与不明原因神经系统疾病相关的大疱性类天疱疮的迟发性皮肤表现
Case Rep Oncol. 2021 Jun 15;14(2):861-867. doi: 10.1159/000514806. eCollection 2021 May-Aug.
2
Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.与抗程序性细胞死亡蛋白1和抗程序性细胞死亡配体1治疗相关的大疱性类天疱疮:文献综述
Acta Derm Venereol. 2021 Jan 20;101(1):adv00377. doi: 10.2340/00015555-3740.
3
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.黏膜类天疱疮、大疱性类天疱疮与抗程序性死亡蛋白1/程序性死亡配体1:1例老年女性在帕博利珠单抗治疗转移性黑色素瘤后发生黏膜类天疱疮的病例报告及文献复习
Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.
4
Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.一名黑色素瘤患者在帕博利珠单抗诱导的大疱性类天疱疮皮损部位出现皮肤转移。
Immunotherapy. 2022 Dec;14(17):1377-1382. doi: 10.2217/imt-2022-0113. Epub 2022 Dec 6.
5
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.一名接受派姆单抗治疗转移性黑色素瘤的患者出现迟发性泛发性类大疱性类天疱疮样反应。
Australas J Dermatol. 2017 Aug;58(3):e109-e112. doi: 10.1111/ajd.12488. Epub 2016 May 11.
6
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.老年女性非小细胞肺癌患者应用帕博利珠单抗治疗后发生大疱性类天疱疮:病例报告及文献复习。
J Oncol Pharm Pract. 2021 Apr;27(3):727-733. doi: 10.1177/1078155220946370. Epub 2020 Aug 9.
7
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.PD-1 和 PD-L1 抑制剂相关大疱性类天疱疮的研究综述。
Int J Dermatol. 2018 Jun;57(6):664-669. doi: 10.1111/ijd.13984. Epub 2018 Apr 6.
8
Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.抗程序性死亡受体配体1(PD-L1)药物继发的大疱性皮肤病:一例病例报告及文献复习
Dermatol Online J. 2019 Oct 15;25(10):13030/qt7qg9675d.
9
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应:皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
10
Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.伪装成离心性环状红斑的大疱性类天疱疮
Acta Dermatovenerol Croat. 2017 Oct;25(3):255-256.

引用本文的文献

1
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.帕博利珠单抗诱导的大疱性类天疱疮临床特征分析
Front Oncol. 2023 Mar 3;13:1095694. doi: 10.3389/fonc.2023.1095694. eCollection 2023.
2
A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma.1例因长期使用信迪利单抗治疗肾细胞癌导致的系统性重症大疱性类天疱疮病例。
Clin Cosmet Investig Dermatol. 2022 Aug 10;15:1611-1614. doi: 10.2147/CCID.S374449. eCollection 2022.
3
Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

本文引用的文献

1
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.根据美国国立综合癌症网络(NCCN)指南及证据水平对美国食品药品监督管理局(FDA)批准的免疫检查点抑制剂适应症的综述。
Cancers (Basel). 2020 Mar 20;12(3):738. doi: 10.3390/cancers12030738.
2
Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita).日本天疱疮(包括获得性大疱性表皮松解症)管理指南。
J Dermatol. 2019 Dec;46(12):1102-1135. doi: 10.1111/1346-8138.15111. Epub 2019 Oct 24.
3
Nonbullous pemphigoid secondary to PD-1 inhibition.
免疫检查点抑制剂相关的皮肤不良反应:一篇综述文章。
Curr Oncol. 2022 Apr 18;29(4):2871-2886. doi: 10.3390/curroncol29040234.
4
Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.免疫检查点抑制剂引起的口腔免疫相关不良事件:唾液腺功能障碍和黏膜疾病
Cancers (Basel). 2022 Feb 4;14(3):792. doi: 10.3390/cancers14030792.
PD-1抑制继发的非大疱性类天疱疮
JAAD Case Rep. 2019 Oct 3;5(10):898-903. doi: 10.1016/j.jdcr.2019.07.015. eCollection 2019 Oct.
4
Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.纳武单抗相关的大疱性类天疱疮反应涉及多个表位。
Eur J Dermatol. 2019 Oct 1;29(5):552-554. doi: 10.1684/ejd.2019.3619.
5
Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.评估大疱性类天疱疮黏膜受累的患病率。
JAMA Dermatol. 2019 Feb 1;155(2):166-171. doi: 10.1001/jamadermatol.2018.5049.
6
Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.黏膜类天疱疮、大疱性类天疱疮与抗程序性死亡蛋白1/程序性死亡配体1:1例老年女性在帕博利珠单抗治疗转移性黑色素瘤后发生黏膜类天疱疮的病例报告及文献复习
Front Med (Lausanne). 2018 Sep 27;5:268. doi: 10.3389/fmed.2018.00268. eCollection 2018.
7
Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma.与伊匹木单抗治疗晚期转移性黑色素瘤相关的大疱性类天疱疮。
JRSM Open. 2018 Oct 3;9(10):2054270418793029. doi: 10.1177/2054270418793029. eCollection 2018 Oct.
8
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病:一项回顾性分析,评估了临床和组织病理学特征、频率以及对癌症治疗的影响。
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.
9
A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.一例纳武利尤单抗诱导的大疱性类天疱疮:程序性细胞死亡蛋白 1/程序性死亡配体 1 抑制剂相关皮肤毒性的综述及诊断与管理建议。
Oncologist. 2018 Oct;23(10):1119-1126. doi: 10.1634/theoncologist.2018-0128. Epub 2018 Jul 17.
10
Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.一名默克尔细胞癌患者出现的帕博利珠单抗相关黏膜类天疱疮。
Br J Dermatol. 2018 Oct;179(4):993-994. doi: 10.1111/bjd.16780. Epub 2018 Jul 23.